

SAN ANTONIO
LIVER CANCER SYMPOSIUM

DAY ONE - THURSDAY, OCTOBER 8, 2026		
7:00–8:00 a.m.	Registration and Breakfast	
8:00–8:05 a.m.	WELCOME AND OPENING REMARKS	
	Lei Zheng, MD, PhD — Executive Director of Mays Cancer Center at UT Health San Antonio	
	Sukeshi Arora, MD — Mays Cancer Center at UT Health San Antonio	
	Danielle Fritze, MD — Mays Cancer Center at UT Health San Antonio	
PLENARY SESSION		
8:10–9:15 a.m.	PLENARY 1 Moderator: Danielle Fritze, MD — Mays Cancer Center at UT Health San Antonio Speaker: Ekihiro Seki, MD, PhD — Cedars-Sinai Medical Center	
	8:10–8:55 a.m. Evolution of Liver	
	9:00–9:15 a.m. Q&A	
9:20–10:35 a.m.	PROGRAM A-SALON A,B, & C	PROGRAM B-SALON D
	PRECLINICAL AND TRANSLATIONAL – LIVER CANCER	UPDATES IN COLON AND RECTAL CANCER
	Moderators: LuZhe Sun, PhD and Peng Zhao, PhD — UT Health San Antonio	Moderator: Alicia Logue, MD — Mays Cancer Center at UT Health San Antonio
	9:20–9:35 a.m. Wei Qiu, PhD — Loyola University Chicago	Screening GI: Douglas K. Rex, MD — Indiana University School of Medicine
	9:35–9:50 a.m. Xiaoli Sun, MD, PhD- UT Health San Antonio	Radiation for Rectal Cancer: Amy Le, MD, MPH — UT Health San Antonio
9:50–10:05 a.m.	Treating HCC by Targeting Cell Cycle in Preclinical Models: LuZhe Sun, PhD -UT Health San Antonio	Liver Metastases: Jonathan Cullen , MD- UT Health San Antonio
10:05–10:20 a.m.	Q & A Panel Discussion	Q&A Panel Discussion
10:20-10:45 a.m.	Break, Networking & Exhibits	
10:50–12:00 p.m.	PROGRAM A-SALON A, B, & C	PROGRAM B- SALON D
	HEPATOLOGY	CHOLANGIOCARCINOMA
	Moderator: Jan Petrasek, MD — UT Health San Antonio	Moderator: Milind M. Javle, MD- UT MD Anderson Houston
	10:50–11:05 a.m. Reducing Disparities Across the HCC Care Continuum: Nicole Rich, MD — UT Southwestern Medical Center	Resectable Surgeon: Ashish Saharia, MD — Houston Methodist Department of Surgery
	11:05-11:20 a.m. Fatty Liver Therapies: Mazen Noureddin, MD — Houston Methodist Academic Medicine Associates	Therapeutics: Tannaz Armaghany, MD- Baylor College of Medicine
11:20-11:35 a.m.	Emerging Therapies in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Eric Lawitz, MD — Texas Liver Institute	Radiation Oncology: Randa Tao, MD — Mayo Clinic
11:35 -11:50 a.m.	Q&A Panel Discussion	Q&A Panel Discussion
12:00-1:15 p.m.	Lunch Product Theater -AstraZeneca Key Considerations When Choosing a First-Line Treatment Option for Unresectable Hepatocellular Carcinoma Speaker: Maen Abdelrahim, MD, PhD, PharmD — Houston Methodist	
1:20-2:15 p.m.	PROGRAM A- SALON A, B, & C	
	EPIDEMIOLOGY	
	Moderator: Amelie Ramirez, DrPH, MPH — UT Health San Antonio	
	1:20-1:35 p.m. Glucagon-like peptide-1 receptor agonist for primary prevention of hepatocellular carcinoma in high-risk patients: A real-world analysis across metabolic, viral, alcoholic, and hereditary liver disease: Colton Jones, MD — UT Health San Antonio	
	1:35–1:50 p.m. Under the radar: An established and some emerging risk factors for liver cancer: Martin Lajous, MD, ScD- National Institute of Public Health of Mexico	
1:50-2:00 p.m.	Small Oral Abstract Presentation: Katherine Hathaway, MS, MPH	
2:00-2:15 p.m.	Q&A Panel Discussion	
2:15-2:40 p.m.	Break, Networking & Exhibits	
2:45- 4:00 p.m.	PROGRAM A-SALON A,B, & C	PROGRAM B- SALON D
	HCC UPDATES IN SYSTEMIC THERAPEUTICS	GENETICS VS GENOMICS IN GI CANCERS
	Moderator: Maen Abdelrahim, MD, PhD, PharmD — Houston Methodist	Case-Based study; Dr. Jessica Jones
	2:45-3:00 p.m. First-Line Therapy: Sukeshi Arora, MD — Mays Cancer Center at UT Health San Antonio	Care Cancer Risk Reduction and Education Program: Jessica Trevino Jones, MD at Mays Cancer Center at UT Health San Antonio
	3:00-3:15 p.m. Second-Line Therapy: Julie Rowe, MD — UT Health Houston	Genetics and Genomics in the South Texas Region: Marcela Mazo Canola, MD — Mays Cancer Center at UT Health San Antonio
3:15-3:30 p.m.	New Therapies: Maen Abdelrahim, MD, PhD, PharmD — Houston Methodist	Genomics: Adetunji Toriola, MD, PhD, Washington University in St. Louis
3:30-3:40 p.m.	Small Oral Abstract Presentation: Dr. Boris Pasche	Small Oral Abstract Presentation: Dr. Subash Khadka
3:40-4:00 p.m.	Q&A Panel Discussion	Q&A Panel Discussion
4:00 p.m.	Day 1 Adjournment	